Cargando…

A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings

Detection of unknown single nucleotide polymorphism (SNP) relies on large scale sequencing expeditions of genomic fragments or complex high-throughput chip technology. We describe a simplified strategy for fluorimetric detection of known and unknown SNP by proportional hybridization to oligonucleoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ena, Adams, Sharon, Zhao, Yingdong, Panelli, Monica, Simon, Richard, Klein, Harvey, Marincola, Francesco M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC202360/
https://www.ncbi.nlm.nih.gov/pubmed/14527341
http://dx.doi.org/10.1186/1479-5876-1-4
_version_ 1782120951774707712
author Wang, Ena
Adams, Sharon
Zhao, Yingdong
Panelli, Monica
Simon, Richard
Klein, Harvey
Marincola, Francesco M
author_facet Wang, Ena
Adams, Sharon
Zhao, Yingdong
Panelli, Monica
Simon, Richard
Klein, Harvey
Marincola, Francesco M
author_sort Wang, Ena
collection PubMed
description Detection of unknown single nucleotide polymorphism (SNP) relies on large scale sequencing expeditions of genomic fragments or complex high-throughput chip technology. We describe a simplified strategy for fluorimetric detection of known and unknown SNP by proportional hybridization to oligonucleotide arrays based on optimization of the established principle of signal loss or gain that requires a drastically reduced number of matched or mismatched probes. The array consists of two sets of 18-mer oligonucleotide probes. One set includes overlapping oligos with 4-nucleotide tiling representing an arbitrarily selected "consensus" sequence (consensus-oligos), the other includes oligos specific for known SNP within the same genomic region (variant-oligos). Fluorescence-labeled DNA amplified from a homozygous source identical to the consensus represents the reference target and is co-hybridized with a differentially-labeled test sample. Lack of hybridization of the test sample to consensus- with simultaneous hybridization to variant-oligos designates a known allele. Lack of hybridization to consensus- and variant-oligos indicates a new allele. Detection of unknown variants in heterozygous samples depends upon fluorimetric analysis of signal intensity based on the principle that homozygous samples generate twice the amount of signal. This method can identify unknown SNP in heterozygous conditions with a sensitivity of 82% and specificity of 90%. This strategy should dramatically increase the efficiency of SNP detection throughout the human genome and will decrease the cost and complexity of applying genomic wide analysis in the context of clinical trials.
format Text
id pubmed-202360
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-2023602003-10-01 A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings Wang, Ena Adams, Sharon Zhao, Yingdong Panelli, Monica Simon, Richard Klein, Harvey Marincola, Francesco M J Transl Med Methodology Detection of unknown single nucleotide polymorphism (SNP) relies on large scale sequencing expeditions of genomic fragments or complex high-throughput chip technology. We describe a simplified strategy for fluorimetric detection of known and unknown SNP by proportional hybridization to oligonucleotide arrays based on optimization of the established principle of signal loss or gain that requires a drastically reduced number of matched or mismatched probes. The array consists of two sets of 18-mer oligonucleotide probes. One set includes overlapping oligos with 4-nucleotide tiling representing an arbitrarily selected "consensus" sequence (consensus-oligos), the other includes oligos specific for known SNP within the same genomic region (variant-oligos). Fluorescence-labeled DNA amplified from a homozygous source identical to the consensus represents the reference target and is co-hybridized with a differentially-labeled test sample. Lack of hybridization of the test sample to consensus- with simultaneous hybridization to variant-oligos designates a known allele. Lack of hybridization to consensus- and variant-oligos indicates a new allele. Detection of unknown variants in heterozygous samples depends upon fluorimetric analysis of signal intensity based on the principle that homozygous samples generate twice the amount of signal. This method can identify unknown SNP in heterozygous conditions with a sensitivity of 82% and specificity of 90%. This strategy should dramatically increase the efficiency of SNP detection throughout the human genome and will decrease the cost and complexity of applying genomic wide analysis in the context of clinical trials. BioMed Central 2003-08-20 /pmc/articles/PMC202360/ /pubmed/14527341 http://dx.doi.org/10.1186/1479-5876-1-4 Text en Copyright © 2003 Wang et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Methodology
Wang, Ena
Adams, Sharon
Zhao, Yingdong
Panelli, Monica
Simon, Richard
Klein, Harvey
Marincola, Francesco M
A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title_full A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title_fullStr A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title_full_unstemmed A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title_short A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
title_sort strategy for detection of known and unknown snp using a minimum number of oligonucleotides applicable in the clinical settings
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC202360/
https://www.ncbi.nlm.nih.gov/pubmed/14527341
http://dx.doi.org/10.1186/1479-5876-1-4
work_keys_str_mv AT wangena astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT adamssharon astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT zhaoyingdong astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT panellimonica astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT simonrichard astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT kleinharvey astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT marincolafrancescom astrategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT wangena strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT adamssharon strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT zhaoyingdong strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT panellimonica strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT simonrichard strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT kleinharvey strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings
AT marincolafrancescom strategyfordetectionofknownandunknownsnpusingaminimumnumberofoligonucleotidesapplicableintheclinicalsettings